

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 5 (canceled)

6. (currently amended) An isolated antibody ~~The antibody of claim 4~~, wherein said antibody ~~further comprises complementarity determining regions (CDRs) having the following sequences:~~

- a) an antibody heavy chain having CDRs comprising CDR1 corresponding to amino acids 31 to 35 of SEQ ID NO:1 (aa 31-35), CDR2 corresponding to amino acids 50 to 66 of SEQ ID NO:1, (aa 50-66) and CDR3 corresponding to amino acids 98 to 108 (aa 98-108) of SEQ ID NO:1, wherein amino acid 31 can be asparagine or serine, amino acid 66 can be glycine or can be deleted, and amino acid 104 can be glutamic acid or aspartic acid; and
- b) an antibody light chain having CDRs comprising CDR1 corresponding to amino acids 18 to 34 or 24 to 34 of SEQ ID NO:2(aa 18-34 or aa 24-34), CDR2 corresponding to amino acids 50 to 56 of SEQ ID NO:2, (aa 50-56) and CDR3 corresponding to amino acids 89 to 98(aa 89-98) of SEQ ID NO:2, wherein amino acid 96 can be proline or isoleucine, and amino acid 98 can be phenylalanine or can be deleted.

7. (currently amended) An isolated antibody ~~according to claim 4~~, wherein said antibody ~~further~~ comprises:

- a) a heavy chain comprising a heavy chain variable region (VH) of SEQ ID NO:1, wherein amino acid (aa) 30 is serine or arginine, aa amino acid 31 is asparagine or serine, aa amino acid 94 is histidine or tyrosine and aa- amino acid 104 is aspartic acid

or glutamic acid, wherein said heavy chain further comprising comprises a human heavy chain constant region (CH); and

b) a light chain comprising a light chain variable region (VL) of SEQ ID NO:2, wherein aa amino acid 96 is proline or isoleucine, aa amino acid 100 is proline or glutamine, aa amino acid 103 is arginine or lysine, aa amino acid 104 is valine or leucine and aa amino acid 105 is aspartic acid or glutamic acid, and wherein said light chain further comprising comprises a human light chain constant region(CL).

8. (currently amended) The antibody of claim 7, wherein the heavy chain amino acids 30, 31, 94 and 104 are the following:

- a) aa amino acid 30 is arginine Arg, aa amino acid 31 is asparagine Asn, aa amino acid 94 is tyrosine Tyr and aa amino acid 104 is aspartic acid Asp, or
- b) aa amino acid 30 is arginine Arg, aa amino acid 31 is serine Ser, aa amino acid 94 is tyrosine Tyr and aa amino acid 104 is aspartic acid Asp, or
- c) aa amino acid 30 is serine Ser, aa amino acid 31 is asparagine Asn, aa amino acid 94 is histidine His and aa amino acid 104 is glutamic acid Glu.

9. (currently amended) The antibody of claim 7, wherein the light chain amino acids 96, 100, 103, 104 and 105 are the following:

- a) aa amino acid 96 is proline Pro, aa amino acid 100 is proline Pro, aa amino acid 103 is lysine Lys, aa amino acid 104 is valine Val and aa amino acid 105 is aspartic acid Asp, or
- b) aa amino acid 96 is isoleucine Ile, aa amino acid 100 is glutamine Glu, aa amino acid 103 is arginine Arg, aa amino acid 104 is leucine Leu and aa amino acid 105 is glutamic acid Glu.

10. (currently amended) The antibody of claim 4 6 wherein said antibody is obtainable from a hybridoma cell line consisting of the group selected from <IGF-1R> HuMab Clone 1a, <IGF-1R> HuMab Clone 23 and <IGF-1R HuMab Clone 8.

11. (currently amended) A composition comprising the antibody of claim 4 6 and a pharmaceutically acceptable carrier or diluent.

Claims 12 to 22 (canceled)

23. (currently amended) A composition comprising the antibody of claim 6 7 and a pharmaceutically acceptable carrier or diluent.

24. (new) A composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier or diluent.

25. (new) A composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier or diluent.

26. (new) A composition comprising the antibody of claim 10 and a pharmaceutically acceptable carrier or diluent.